Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 24,865 shares of the biopharmaceutical company’s stock after selling 984 shares during the period. Illinois Municipal Retirement Fund’s holdings in Regeneron Pharmaceuticals were worth $19,212,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of REGN. Nordea Investment Management AB increased its stake in Regeneron Pharmaceuticals by 118.1% during the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock worth $105,810,000 after acquiring an additional 74,350 shares during the last quarter. Lockheed Martin Investment Management Co. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $2,702,000. Asio Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $3,422,000. Robeco Institutional Asset Management B.V. grew its holdings in shares of Regeneron Pharmaceuticals by 116.6% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock worth $202,114,000 after purchasing an additional 140,966 shares during the period. Finally, AE Wealth Management LLC increased its position in Regeneron Pharmaceuticals by 36.7% during the 4th quarter. AE Wealth Management LLC now owns 5,474 shares of the biopharmaceutical company’s stock worth $4,226,000 after purchasing an additional 1,470 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on REGN. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Cantor Fitzgerald reduced their target price on shares of Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating on the stock in a report on Monday, July 6th. Canaccord Genuity Group decreased their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Finally, Morgan Stanley lowered their price target on Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating for the company in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $787.67.

Regeneron Pharmaceuticals Stock Up 1.3%

Shares of NASDAQ:REGN opened at $664.45 on Thursday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $821.11. The company has a 50 day moving average of $642.36 and a two-hundred day moving average of $719.45. The company has a market capitalization of $70.25 billion, a price-to-earnings ratio of 16.19, a price-to-earnings-growth ratio of 1.45 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same period in the previous year, the company posted $8.22 earnings per share. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.16 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.